Susquehanna International Group’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$13.2M Buy
234,271
+164,869
+238% +$10.7M ﹤0.01% 2716
2025
Q4
$5.56M Buy
69,402
+33,589
+94% +$2.26M ﹤0.01% 3848
2025
Q3
$1.75M Sell
35,813
-31,014
-46% -$1.92M ﹤0.01% 6081
2025
Q2
$4.99M Buy
66,827
+7,394
+12% +$490K ﹤0.01% 3971
2025
Q1
$3.78M Buy
59,433
+37,429
+170% +$2.55M ﹤0.01% 4193
2024
Q4
$1.72M Buy
+22,004
New +$1.77M ﹤0.01% 5656
2024
Q3
Sell
-13,583
Closed -$1.1M 12395
2024
Q2
$1.12M Sell
13,583
-1,121
-8% -$98.6K ﹤0.01% 6312
2024
Q1
$1.25M Sell
14,704
-24,396
-62% -$1.91M ﹤0.01% 6357
2023
Q4
$3.34M Buy
39,100
+7,333
+23% +$634K ﹤0.01% 4392
2023
Q3
$2.85M Buy
31,767
+15,586
+96% +$1.39M ﹤0.01% 4474
2023
Q2
$1.38M Sell
16,181
-5,712
-26% -$483K ﹤0.01% 5954
2023
Q1
$1.81M Buy
21,893
+9,536
+77% +$772K ﹤0.01% 5354
2022
Q4
$972K Sell
12,357
-27,307
-69% -$2.19M ﹤0.01% 6256
2022
Q3
$2.94M Buy
39,664
+29,328
+284% +$2.11M ﹤0.01% 4144
2022
Q2
$674K Buy
10,336
+2,539
+33% +$150K ﹤0.01% 7528
2022
Q1
$493K Sell
7,797
-27,234
-78% -$1.48M ﹤0.01% 9022
2021
Q4
$1.86M Sell
35,031
-15,199
-30% -$926K ﹤0.01% 5683
2021
Q3
$3.55M Sell
50,230
-32,508
-39% -$2.05M ﹤0.01% 4601
2021
Q2
$5.51M Buy
82,738
+76,138
+1,154% +$5.39M ﹤0.01% 3868
2021
Q1
$733K Buy
6,600
+1,238
+23% +$153K ﹤0.01% 8539
2020
Q4
$637K Sell
5,362
-23,440
-81% -$2.52M ﹤0.01% 7753
2020
Q3
$2.51M Sell
28,802
-9,667
-25% -$845K ﹤0.01% 4181
2020
Q2
$3.44M Buy
38,469
+23,491
+157% +$2.37M ﹤0.01% 3573
2020
Q1
$1.49M Buy
14,978
+9,054
+153% +$982K ﹤0.01% 4506
2019
Q4
$681K Sell
5,924
-19,536
-77% -$2.36M ﹤0.01% 6312
2019
Q3
$3.21M Buy
25,460
+5,319
+26% +$675K ﹤0.01% 3384
2019
Q2
$2.42M Buy
+20,141
New +$1.98M ﹤0.01% 3802
2019
Q1
Sell
-4,049
Closed -$368K 9235
2018
Q4
$405K Buy
+4,049
New +$425K ﹤0.01% 6424
2018
Q3
Sell
-32,310
Closed -$3.34M 9607
2018
Q2
$2.9M Buy
+32,310
New +$2.73M ﹤0.01% 3434
2018
Q1
Sell
-4,059
Closed -$278K 9645
2017
Q4
$236K Buy
+4,059
New +$214K ﹤0.01% 7974
2017
Q3
Sell
-11,260
Closed -$445K 9124
2017
Q2
$445K Buy
+11,260
New +$462K ﹤0.01% 6859
2017
Q1
Sell
-78,842
Closed -$3.17M 9325
2016
Q4
$3.17M Buy
+78,842
New +$2.97M ﹤0.01% 3132
2016
Q1
Sell
-6,642
Closed -$214K 9264
2015
Q4
$214K Sell
6,642
-2,664
-29% -$86.4K ﹤0.01% 8310
2015
Q3
$301K Sell
9,306
-42,689
-82% -$1.61M ﹤0.01% 8032
2015
Q2
$2.15M Buy
51,995
+18,179
+54% +$766K ﹤0.01% 4565
2015
Q1
$1.52M Buy
33,816
+8,538
+34% +$357K ﹤0.01% 4890
2014
Q4
$945K Buy
+25,278
New +$926K ﹤0.01% 5982
2014
Q3
Sell
-24,992
Closed -$882K 9623
2014
Q2
$882K Buy
24,992
+14,607
+141% +$488K ﹤0.01% 6312
2014
Q1
$338K Sell
10,385
-9,165
-47% -$350K ﹤0.01% 7408
2013
Q4
$824K Buy
19,550
+13,901
+246% +$572K ﹤0.01% 5835
2013
Q3
$225K Buy
+5,649
New +$237K ﹤0.01% 7598

Other funds holding HAE

Susquehanna International Group's HAE Position: Q1 2026 in Review

Susquehanna International Group increased its Haemonetics (HAE) stake by 238% in Q1 2026, buying an estimated $10.7M and bringing the position to 234,271 shares worth $13.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2716.

Susquehanna International Group first reported a position in HAE in Q3 2013 and has held it in 41 quarters since. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Susquehanna International Group held 234,271 shares of Haemonetics worth $13.2M as of Q1 2026.
  • Susquehanna International Group bought 164,869 Haemonetics shares in Q1 2026, an estimated $10.7M.
  • Haemonetics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2716 holding.
  • Susquehanna International Group first reported a position in Haemonetics in Q3 2013 and has held it in 41 quarters since.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.